Incyte Corp Company Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the competitive landscape for INCYTE CORP, and when can generic versions of INCYTE CORP drugs launch?
INCYTE CORP has three approved drugs.
There are seventeen US patents protecting INCYTE CORP drugs.
There are three hundred and fifty-nine patent family members on INCYTE CORP drugs in forty-nine countries and thirty-seven supplementary protection certificates in eighteen countries.
Summary for Incyte Corp
| International Patents: | 359 |
| US Patents: | 17 |
| Tradenames: | 3 |
| Ingredients: | 2 |
| NDAs: | 3 |
Drugs and US Patents for Incyte Corp
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Incyte Corp | JAKAFI | ruxolitinib phosphate | TABLET;ORAL | 202192-005 | Nov 16, 2011 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Incyte Corp | PEMAZYRE | pemigatinib | TABLET;ORAL | 213736-002 | Apr 17, 2020 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Incyte Corp | OPZELURA | ruxolitinib phosphate | CREAM;TOPICAL | 215309-001 | Sep 21, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Incyte Corp | JAKAFI | ruxolitinib phosphate | TABLET;ORAL | 202192-001 | Nov 16, 2011 | RX | Yes | No | 7,598,257*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Incyte Corp | JAKAFI | ruxolitinib phosphate | TABLET;ORAL | 202192-003 | Nov 16, 2011 | RX | Yes | No | 8,822,481*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Incyte Corp | JAKAFI | ruxolitinib phosphate | TABLET;ORAL | 202192-005 | Nov 16, 2011 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for INCYTE CORP drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg | ➤ Subscribe | 2015-12-17 |
International Patents for Incyte Corp Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Serbia | 58449 | ⤷ Try a Trial |
| Slovenia | 2348023 | ⤷ Try a Trial |
| Spain | 2373688 | ⤷ Try a Trial |
| Israel | 192019 | ⤷ Try a Trial |
| Israel | 248938 | ⤷ Try a Trial |
| New Zealand | 730134 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Incyte Corp Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1966202 | 8/2013 | Austria | ⤷ Try a Trial | PRODUCT NAME: RUXOLITINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/12/773/001-003 20120823 |
| 2455382 | 300870 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: RUXOLITINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/12/773/001-016 20150313 |
| 2861595 | 21C1041 | France | ⤷ Try a Trial | PRODUCT NAME: PEMIGATINIB OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/21/1535 20210329 |
| 1966202 | 92137 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: RUXOLITINIB,OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES |
| 1966202 | SPC/GB13/005 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: RUXOLITINIB, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; REGISTERED: UK EU/1/12/773/001 20120828; UK EU/1/12/773/002 20120828; UK EU/1/12/773/003 20120828 |
| 2861595 | 132021000000140 | Italy | ⤷ Try a Trial | PRODUCT NAME: PEMIGATINIB O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(PEMAZYRE); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/21/1535, 20210329 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
